CN119789859A - 非酒精性脂肪肝病的治疗 - Google Patents

非酒精性脂肪肝病的治疗 Download PDF

Info

Publication number
CN119789859A
CN119789859A CN202380045597.9A CN202380045597A CN119789859A CN 119789859 A CN119789859 A CN 119789859A CN 202380045597 A CN202380045597 A CN 202380045597A CN 119789859 A CN119789859 A CN 119789859A
Authority
CN
China
Prior art keywords
compound
dose
human subject
nucleotide sequence
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380045597.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·哈米尔顿
B·D·吉文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Pharmaceuticals Inc
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of CN119789859A publication Critical patent/CN119789859A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202380045597.9A 2022-04-08 2023-04-07 非酒精性脂肪肝病的治疗 Pending CN119789859A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329081P 2022-04-08 2022-04-08
US63/329,081 2022-04-08
US202263401858P 2022-08-29 2022-08-29
US63/401,858 2022-08-29
PCT/US2023/065487 WO2023196941A1 (en) 2022-04-08 2023-04-07 Treatment of a non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
CN119789859A true CN119789859A (zh) 2025-04-08

Family

ID=86286479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380045597.9A Pending CN119789859A (zh) 2022-04-08 2023-04-07 非酒精性脂肪肝病的治疗

Country Status (6)

Country Link
US (1) US20250283089A1 (https=)
EP (1) EP4504337A1 (https=)
JP (1) JP2025511854A (https=)
CN (1) CN119789859A (https=)
CA (1) CA3247602A1 (https=)
WO (1) WO2023196941A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025074157A1 (en) * 2023-10-06 2025-04-10 Glaxosmithkline Intellectual Property (No.3) Limited Treatment of a non-alcoholic fatty liver disease
WO2025162271A1 (zh) * 2024-02-03 2025-08-07 北京福元医药股份有限公司 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102515329B1 (ko) 2016-03-07 2023-03-29 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
MX2018009853A (es) 2016-09-02 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos de direccion.
MX2020001912A (es) * 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
MX2021003077A (es) 2018-09-19 2021-05-27 Arrowhead Pharmaceuticals Inc Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso.
TW202202153A (zh) * 2020-03-26 2022-01-16 美商艾羅海德製藥公司 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法

Also Published As

Publication number Publication date
US20250283089A1 (en) 2025-09-11
EP4504337A1 (en) 2025-02-12
JP2025511854A (ja) 2025-04-16
WO2023196941A1 (en) 2023-10-12
CA3247602A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
EP3679141B1 (en) Methods and compositions for inhibiting expression of ldha
TWI870358B (zh) 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法
US12582668B2 (en) Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
TW202307207A (zh) 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法
JP2021522804A (ja) Ｆｘｉの発現を低下させるための化合物及び方法
CN119789859A (zh) 非酒精性脂肪肝病的治疗
TW202120104A (zh) 用於治療apoc3相關疾病及病症之方法
JP7846095B2 (ja) Ｚ－ａａｔタンパク質のレベルを低下させる方法
CN120112639A (zh) Angptl3相关疾病和病症的治疗方法
WO2025103391A1 (zh) 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
JP2025032231A (ja) Ｓｅｒｐｉｎｃ１ ｉＲＮＡ組成物およびその使用方法
CN116670278A (zh) 用于降低z-aat蛋白水平的方法
RU2847618C2 (ru) Способы лечения дефицита альфа-1-антитрипсина (aatd)
CN121969377A (zh) 非酒精性脂肪性肝病的治疗
WO2025074157A1 (en) Treatment of a non-alcoholic fatty liver disease
WO2026077400A1 (zh) 用于治疗心血管相关疾病的siRNA及其缀合物和应用
TW202430635A (zh) 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法
HK40026540A (en) Methods and compositions for inhibiting expression of ldha

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124992

Country of ref document: HK